Day‐29 Minimal Residual Disease and Candidate Adverse Molecular Alterations for Survival Stratification in a TARGET/cBioPortal Acute Lymphoblastic Leukemia Cohort
Hematological Oncology · 2026-11 · 44 (6)
DOI: 10.1002/hon.70297 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematological Oncology, online erschienen am 20.11.2026. Verfasst von Yang Zhai und 2 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
Day‐29 minimal residual disease (MRD) is central to risk assessment in pediatric acute lymphoblastic leukemia (ALL), but MRD alone may not fully explain outcome heterogeneity. We performed a retrospective patient‐level analysis of the public TARGET/cBioPortal cohort to evaluate whether MRD and candidate adverse molecular alterations (CAMA) jointly stratify event‐free survival (EFS) and overall survival (OS). The roster contained 1551 patients; MRD was available for 1534, including 1058 below 0.01% and 476 at or above 0.01%. EFS and OS source fields were available for 1535, with 399 coded EFS events and 254 deaths. Their intersection with available MRD contained 1524 patients, 391 EFS events and 246 deaths. Molecular profiles were selectively available: 137 patients had mutation profiles and 682 had copy‐number profiles. Source verification did not establish complete CAMA‐negative status, a valid Ph‐like classifier, diagnostic timing of all molecular samples, or alignment of the exported survival clock with MRD sampling. CAMA rules were outcome‐informed, and the original fully adjusted model had coding and estimation problems. Accordingly, historical HRs and C‐index differences are disclosed for reproducibility but are not retained as valid prognostic estimates. The clinical‐molecular research framework is retained as the study question; joint survival stratification and incremental discrimination are not established by this dataset.
Zitieren
APA
Zhai, Y., Yuan, H., & Kong, L. (2026). Day‐29 Minimal Residual Disease and Candidate Adverse Molecular Alterations for Survival Stratification in a TARGET/cBioPortal Acute Lymphoblastic Leukemia Cohort. Hematological Oncology, 44(6). https://doi.org/10.1002/hon.70297
Vancouver
Zhai Y, Yuan H, Kong L. Day‐29 Minimal Residual Disease and Candidate Adverse Molecular Alterations for Survival Stratification in a TARGET/cBioPortal Acute Lymphoblastic Leukemia Cohort. Hematological Oncology. 2026;44(6). doi:10.1002/hon.70297
BibTeX
@article{Zhai2026,
author = {Zhai, Yang and Yuan, Hao and Kong, Lingjun},
title = {Day‐29 Minimal Residual Disease and Candidate Adverse Molecular Alterations for Survival Stratification in a TARGET/cBioPortal Acute Lymphoblastic Leukemia Cohort},
journal = {Hematological Oncology},
year = {2026},
volume = {44},
number = {6},
doi = {10.1002/hon.70297}
}
EUVIMED